Bio Other Operating Expenses from 2010 to 2024
| BPTH Stock | USD 2.61 0.05 1.88% |
Other Operating Expenses | First Reported 2004-09-30 | Previous Quarter 3.3 M | Current Value 3 M | Quarterly Volatility 1.3 M |
Check Bio Path financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio main balance sheet or income statement drivers, such as Depreciation And Amortization of 179.9 K, Interest Expense of 31.2 K or Selling General Administrative of 3.9 K, as well as many exotic indicators such as Price To Sales Ratio of 9.4 K, Dividend Yield of 0.0 or PTB Ratio of 9.54. Bio financial statements analysis is a perfect complement when working with Bio Path Valuation or Volatility modules.
Bio | Other Operating Expenses |
Latest Bio Path's Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Bio Path Holdings over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bio Path Holdings. It is also known as Bio Path overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Bio Path's Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bio Path's overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Bio Other Operating Expenses Regression Statistics
| Arithmetic Mean | 8,018,264 | |
| Geometric Mean | 5,552,685 | |
| Coefficient Of Variation | 62.42 | |
| Mean Deviation | 3,969,071 | |
| Median | 8,488,000 | |
| Standard Deviation | 5,004,877 | |
| Sample Variance | 25T | |
| Range | 16.5M | |
| R-Value | 0.98 | |
| Mean Square Error | 1.1T | |
| R-Squared | 0.96 | |
| Slope | 1,095,251 | |
| Total Sum of Squares | 350.7T |
Bio Other Operating Expenses History
About Bio Path Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Bio Path income statement, its balance sheet, and the statement of cash flows. Bio Path investors use historical funamental indicators, such as Bio Path's Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although Bio Path investors may use each financial statement separately, they are all related. The changes in Bio Path's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bio Path's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bio Path Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bio Path. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 15.8 M | 16.6 M |
Pair Trading with Bio Path
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Path position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Path will appreciate offsetting losses from the drop in the long position's value.Moving together with Bio Stock
| 0.66 | EDSA | Edesa Biotech Financial Report 9th of May 2024 | PairCorr |
Moving against Bio Stock
| 0.79 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.76 | GBIO | Generation BioCo Financial Report 8th of May 2024 | PairCorr |
| 0.63 | LIXT | Lixte Biotechnology Earnings Call This Week | PairCorr |
| 0.58 | GLUE | Monte Rosa Therapeutics Earnings Call This Week | PairCorr |
| 0.46 | ELVN | Enliven Therapeutics Trending | PairCorr |
The ability to find closely correlated positions to Bio Path could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Path when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Path - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Path Holdings to buy it.
The correlation of Bio Path is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Path moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Path Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Path can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Bio Path Correlation against competitors. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Bio Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Bio Path's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (33.63) | Return On Assets (1.03) | Return On Equity (2.20) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.